| 1. |
- Allison, J, et al.
(författare)
-
Geant4 developments and applications
- 2006
-
Ingår i: IEEE TRANSACTIONS ON NUCLEAR SCIENCE. - 0018-9499. ; 53:1, s. 270-278
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 2. |
- Ahn, Jiyoung, et al.
(författare)
-
Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3).
- 2009
-
Ingår i: Human molecular genetics. - : Oxford University Press (OUP). - 1460-2083 .- 0964-6906. ; 18:19, s. 3749-57
-
Tidskriftsartikel (refereegranskat)abstract
- Twin studies suggest a heritable component to circulating sex steroid hormones and sex hormone-binding globulin (SHBG). In the NCI-Breast and Prostate Cancer Cohort Consortium, 874 SNPs in 37 candidate genes in the sex steroid hormone pathway were examined in relation to circulating levels of SHBG (N = 4720), testosterone (N = 4678), 3 alpha-androstanediol-glucuronide (N = 4767) and 17beta-estradiol (N = 2014) in Caucasian men. rs1799941 in SHBG is highly significantly associated with circulating levels of SHBG (P = 4.52 x 10(-21)), consistent with previous studies, and testosterone (P = 7.54 x 10(-15)), with mean difference of 26.9 and 14.3%, respectively, comparing wild-type to homozygous variant carriers. Further noteworthy novel findings were observed between SNPs in ESR1 with testosterone levels (rs722208, mean difference = 8.8%, P = 7.37 x 10(-6)) and SRD5A2 with 3 alpha-androstanediol-glucuronide (rs2208532, mean difference = 11.8%, P = 1.82 x 10(-6)). Genetic variation in genes in the sex steroid hormone pathway is associated with differences in circulating SHBG and sex steroid hormones.
|
|
| 3. |
- Erdelyi, Mate, 1975, et al.
(författare)
-
The Conformational Preferences of Natural and C3-Modified Epothilones in Aqueous Solution
- 2008
-
Ingår i: J. Med. Chem.. - : American Chemical Society (ACS). ; 51:5, s. 1469-73
-
Tidskriftsartikel (refereegranskat)abstract
- The conformational properties of the microtubule-stabilizing agent epothilone A (1a) and its 3-deoxy and 3-deoxy-2,3-didehydro derivatives 2 and 3 have been investigated in aqueous solution by a combination of NMR spectroscopic methods, Monte Carlo conformational searches, and NAMFIS calculations. The tubulinbound conformation of epothilone A (1a), as previously proposed on the basis of solution NMR data, was found to represent a significant fraction of the ensemble of conformations present for the free ligands in aqueous solution.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Harada, K., et al.
(författare)
-
Ionized impurity scattering in n -doped C60 thin films
- 2007
-
Ingår i: Applied Physics Letters. - : AIP Publishing. - 0003-6951 .- 1077-3118. ; 91:9
-
Tidskriftsartikel (refereegranskat)abstract
- Carrier transport in organic films is usually dominated by hopping process, leading to different temperature dependence from that of inorganic crystals. The aurhors demonstrate that n -doped C60 films show temperature dependence analogous to inorganic semiconductors. At low temperatures, the conductivity increases with temperature, around room temperature, a maximum is reached and then the conductivity decreases. These observations are confirmed by the dependence of mobility on doping level. In contrast to previous reports for organic thin films, the C60 films show a decrease of mobility with increasing doping levels, i.e., they follow the well-known Matthiessen rule which is generally observed in inorganic semiconductors. © 2007 American Institute of Physics.
|
|
| 7. |
- Hayek, W, et al.
(författare)
-
The Hamburg/ESO R-process enhanced star survey (HERES) IV. Detailed abundance analysis and age dating of the strongly r-process enhanced stars CS 29491-069 and HE 1219-0312
- 2009
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 504:2, s. 511-524
-
Tidskriftsartikel (refereegranskat)abstract
- We report on a detailed abundance analysis of two strongly r-process enhanced, very metal-poor stars newly discovered in the HERES project, CS 29491-069 ([Fe/H] = -2.51, [r/Fe] = +1.1) and HE 1219-0312 ([Fe/H] = -2.96, [r/Fe] = +1.5). The analysis is based on high-quality VLT/UVES spectra and MARCS model atmospheres. We detect lines of 15 heavy elements in the spectrum of CS 29491-069, and 18 in HE 1219-0312; in both cases including the Th II 4019 angstrom line. The heavy-element abundance patterns of these two stars are mostly well-matched to scaled solar residual abundances not formed by the s-process. We also compare the observed pattern with recent high-entropy wind (HEW) calculations, which assume core-collapse supernovae of massive stars as the astrophysical environment for the r-process, and find good agreement for most lanthanides. The abundance ratios of the lighter elements strontium, yttrium, and zirconium, which are presumably not formed by the main r-process, are reproduced well by the model. Radioactive dating for CS 29491-069 with the observed thorium and rare-earth element abundance pairs results in an average age of 9.5 Gyr, when based on solar r-process residuals, and 17.6 Gyr, when using HEW model predictions. Chronometry seems to fail in the case of HE 1219-0312, resulting in a negative age due to its high thorium abundance. HE 1219-0312 could therefore exhibit an overabundance of the heaviest elements, which is sometimes called an "actinide boost".
|
|
| 8. |
|
|
| 9. |
- Pfeiffer, P, et al.
(författare)
-
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil
- 2006
-
Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 17:2, s. 252-258
-
Tidskriftsartikel (refereegranskat)abstract
- Background: The efficacy of oxaliplatin combined with capecitabine (XELOX) as second-line therapy in patients with advanced colorectal cancer (ACRC) resistant to irinotecan is not well established. Oxaliplatin induces acute, cold-induced neuropathy in most patients. The incidence is claimed to be infusion rate-dependent and therefore a 2-h infusion is recommended. Patients and methods: For practical and economic reasons, but also for patient's convenience, we performed a phase II study to examine XELOX30 (capecitabine 1000 mg/m2 orally twice daily on days 1-14 and oxaliplatin 130 mg/m2 as a 30 min infusion on day 1) in patients with ACRC resistant to irinotecan. In addition the pharmacokinetics of oxaliplatin was studied. Results: From November 2002 to September 2003, 70 patients with ACRC were treated with XELOX30. Median age was 62 (range 33-74 years) years and median performance status was 1 (range 0-2). The median number of courses was four (range 1-12) and median cumulative dose of oxaliplatin was 530 (range 125-1560) mg/m2. The response rate was 17% (95% CI 10-23), median time to progression (TTP) was 5.4 months (95% CI 4.6-6.4) and median survival 9.5 months (95% CI 8.5-11.2). White blood cell count (WBC) and performance status were significantly correlated to TTP. Neurotoxicity was moderate: grade 1 56%, grade 2 17% and grade 3 6%. Other grade 3 toxicities were nausea/ vomiting 9%, diarrhoea 14% and PPE 8%. The maximum blood concentration and total body clearance of oxaliplatin was higher than previously reported in studies examining 2-h infusions, but the volume of distribution and terminal half-life was in close agreement with previous results. Conclusion: XELOX30 is a very convenient second-line regimen in ACRC with an activity and safety profile similar to other oxaliplatin schedules. © 2005 European Society for Medical Oncology.
|
|
